

Substitute for form 1449/PTO			Complete if Known		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/519,436-Conf. #7541	
			Filing Date	December 22, 2004	
			First Named Inventor	Hilde Azijn	
			Art Unit	1648	
			Examiner Name	L. W. Z. Humphrey	
Sheet	1	of	5	Attorney Docket Number	026038.0248PTUS

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ² (if known)				
	1	2003/0190603	10/09/2003	Larder et al.		
	2	2004/0073378	04/15/2004	Dehertogh et al.		
	3	2008/0286754	11/20/2008	Dehertogh et al.		
	4	2009/0061420	03/05/2009	Azjin et al.		
	5	2009/0162867	01/13/2009	Hertogs et al.		
	6	7,058,616	06/06/2006	Larder et al.		
	7	7,217,506	05/15/2007	De Meyer et al.		
	8	7,292,944	11/06/2007	Larder et al.		
	9	7,494,768	02/24/2009	Hertogs et al.		
	10	In the U.S. Patent and Trademark Office, Non-Final Office Action in re: Application No. 10/518,525, dated May 10, 2006, 8 pages.				
	11	In the U.S. Patent and Trademark Office, Final Office Action in re: Application No. 10/518,525, dated February 7, 2007, 6 pages.				
	12	In the U.S. Patent and Trademark Office, Final Office Action in re: Application No. 10/518,525, dated October 18, 2007, 6 pages.				
	13	In the U.S. Patent and Trademark Office, Non-Final Office Action in re: Application No. 10/519,035, dated December 16, 2005, 8 pages.				
	14	In the U.S. Patent and Trademark Office, Non-Final Office Action in re: Application No. 10/399,920, dated August 25, 2005, 10 pages.				
	15	In the U.S. Patent and Trademark Office, Final Office Action in re: Application No. 10/399,920, dated August 4, 2006, 8 pages.				
	16	In the U.S. Patent and Trademark Office, Final Office Action in re: Application No. 10/399,920, dated May 2, 2007, 9 pages.				
	17	In the U.S. Patent and Trademark Office, Non-Final Office Action in re: Application No. 11/933,747, dated August 7, 2009, 7 pages.				
	18	In the U.S. Patent and Trademark Office, Final Office Action in re: Application No. 11/933,747, dated April 5, 2010, 8 pages.				
	19	In the U.S. Patent and Trademark Office, Non-Final Office Action in re: Application No. 12/261,475, dated May 4, 2010, 12 pages.				
	20	In the U.S. Patent and Trademark Office, Non-Final Office Action in re: Application No. 11/613,584, dated March 12, 2009, 8 pages.				
	21	In the U.S. Patent and Trademark Office, Final Office Action in re: Application No. 11/613,584, dated April 15, 2010, 11 pages.				

*EXAMINER: Initials if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).	
Dated: <u>October 18, 2010</u>	Signature: <u>/Therese M. Finan/</u> (Therese M. Finan)

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/519,436-Conf. #7541
				Filing Date	December 22, 2004
				First Named Inventor	Hilde Azijn
				Art Unit	1648
				Examiner Name	L. W. Z. Humphrey
Sheet	2	of	5	Attorney Docket Number	026038.0248PTUS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T‡
		Country Code* - Number* - Kind Code* (if known)	MM-DD-YYYY			
	22	EP 0 422 762	04/17/1991	LARDER et al.		
	23	EP 0 518 557	12/16/1992	HEATH et al.		
	24	WO 96/008580	03/21/1996	MELNICK et al.		
	25	WO 99/067417	12/29/1999	ERICKSON et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ¶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	26	ABREMSKI et al., "pol protein HIV-1"; downloaded from http://www.ncbi.nlm.nih.gov/protein/AAG03320 ; 2000: 1-2.			
	27	BACHELER et al., "Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy," <i>Antimicrobial Agents and Chemotherapy</i> , 2000; 44(9):2475-2484.			
	28	BEERENWINKEL et al., "Diversity and Complexity of HIV-1 Drug Resistance: A Bioinformatics Approach to Predicting Phenotype from Genotype," <i>PNAS</i> , 2002; 99(2):8271-8276.			
	29	CLEVENBERGH et al., "Prevalence of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance-Associated Mutations and Polymorphisms in NNRTI-Naïve HIV-Infected Patients," <i>HIV Clin Trials</i> , 2002; 3(1):36-44.			
	30	CONDRA et al., "Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir," <i>1st International Workshop HIV Drug Resistance and Treatment Strategies and Eradication</i> , 1997; Abstract 47: 48-49.			
	31	CRAIG et al., "HIV Protease Genotype and Viral Sensitivity to HIV Protease Inhibitors Following Saquinavir Therapy," <i>AIDS</i> , 1998; 12:1611-1618.			
	32	D'AQUILA, R., "HIV-1 Chemotherapy and Drug Resistance," <i>Clinical and Diagnostic Virology</i> , 1995; 3:299-316.			
	33	DEEKS et al., "Correlation of Baseline Phenotypic Drug Susceptibility with 16 Week Virologic Response in a Pilot Combination Therapy Study in HIV-infected Patients who Failed Indinavir Therapy," <i>2nd Int'l Workshop on HIV Drug Resistance and Treatment Strategies</i> , Lake Maggiore, Italy, 1998; Abstract 53.			
	34	DESCAMPS et al., "Line Probe Assay for Detection of Human Immunodeficiency Virus type 1 Mutations Conferring Resistance to Nucleoside Inhibitors of Reverse Transcriptase: Comparison with Sequence Analysis," <i>Journal of Clinical Microbiology</i> , 1998; 36(7):2143-2145.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO			Complete if Known		
<p align="center">SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center"><i>(Use as many sheets as necessary)</i></p>			Application Number	10/519,436-Conf. #7541	
			Filing Date	December 22, 2004	
			First Named Inventor	Hilde Azijn	
			Art Unit	1648	
			Examiner Name	L. W. Z. Humphrey	
Sheet	3	of	5	Attorney Docket Number	026038.0248PTUS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	35	EASTMAN et al., "Comparison of Selective Polymerase Chain Reaction Primers and Differential Probe Hybridization of Polymerase Chain Reaction Products for Determination of Relative Amounts of Codon 215 Mutant and Wild-type HIV-1 Population," <i>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</i> , 1995; 9:264-273.	
	36	ESHLEMAN et al., "Analysis of Human Immunodeficiency Virus Type 1 Drug Resistance in Children Receiving Nucleoside Analogue Reverse-Transcriptase Inhibitors plus Nevirapine, Zidovudine, or Zalcitabine (Pediatric AIDS Clinical Trials Group 377)," <i>Journal of Infectious Diseases</i> , 2001; 183:1732-1738.	
	37	ESHLEMAN et al., "HIV-1 isolate 420111k042398 from USA pol protein (pol) gene"; downloaded from http://www.ncbi.nlm.nih.gov/nuccore/AF357746 ; 2002; 1-2.	
	38	FODOR et al., "DNA Sequencing: Massively Parallel Genomics," <i>Science</i> , 1997; 277:393, 395.	
	39	GINGERAS et al., "Use of Self-Sustained Sequence Replication Amplification Reaction to Analyze and Detect Mutations in Zidovudine-Resistant Human Immunodeficiency Virus," <i>The Journal of Infectious Diseases</i> , 1991; 164(6):1066-1074.	
	40	GONZALES et al., "pol protein (HIV-1)" downloaded from http://www.ncbi.nlm.nih.gov/protein/AAK35843 2001; 1-3.	
	41	HERTOGS et al., "A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V," <i>Antimicrobial Agents and Chemotherapy</i> , 2000; 44(3):568-573.	
	42	HIV Database, http://hiv-web.lanl.gov/content/index .	
	43	HOLODNIY et al., "Determination of Human Immunodeficiency Virus RNA in Plasma and Cellular Viral DNA Genotypic Zidovudine Resistance and Viral Load During Zidovudine-Didanosine Combination Therapy," <i>Journal of Virology</i> , 1995; 69(6):3510-3516.	
	44	IVERSEN et al., "Multidrug-Resistant Human Immunodeficiency Virus Type 1 Strains Resulting from Combination Antiretroviral Therapy," <i>Journal of Virology</i> , 1996; 70(2):1086-1090.	
	45	JAPOUR et al., "Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates," <i>Antimicrobial Agents and Chemotherapy</i> , 1993; 37(5):1095-1101.	
	46	KELLAM et al., "Recombinant Virus Assay: A Rapid, Phenotypic Assay for Assessment of Drug Susceptibility of Human Immunodeficiency Virus Type 1 Isolates," <i>Antimicrobial Agents and Chemotherapy</i> , 1994; 38(1):23-30.	
	47	KEMP et al., "Analysis of 5000 HIV-1 Clinical Samples Reveals Complex Non-Nucleoside RT Inhibitor Resistance Patterns," <i>Antiviral Therapy</i> , 1999; 4 (Suppl 1):20.	
	48	KORBER et al., "Numbering Positions in HIV Relative to HXB2CG," <i>Numbering Positions in HIV</i> , 1998; (III):102-111.	
	49	KUSUMI et al., "Human Immunodeficiency Virus Type 1 Envelope Gene Structure and Diversity <i>In Vivo</i> and after Cocultivation <i>In Vitro</i> ," <i>Journal of Virology</i> , 1992; 66(2):875-885.	
	50	LARDER et al., "A Complete Survey in Over 1,500 Clinical HIV-1 Isolates, of Phenotypic and Genotypic Protease Inhibitor Resistance Profiles (Including Gag Cleavage Site Sequences) and Their Relation to Therapy History," <i>International Congress on Drug Therapy in HIV Infections</i> , 1998; 12(4):S11; Abstract Poster, OP3.5.	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO			Complete if Known Application Number 10/519,436-Conf. #7541 Filing Date December 22, 2004 First Named Inventor Hilde Azijn Art Unit 1648 Examiner Name L. W. Z. Humphrey Attorney Docket Number 026038.0248PTUS	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				
Sheet	4	of	5	

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	51	LARDER et al., "Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZI)," <i>Science Reports</i> , 1989; 246(4934):1155-1158.	
	52	MARGOT et al., "Genotypic and Phenotypic Analyses of HIV-1 in Antiretroviral-Experienced Patients Treated with Tenofovir DF," <i>AIDS</i> , 2002; 16:1227-1235.	
	53	MARTINEZ et al., "protease (HIV-1)", downloaded from http://www.ncbi.nlm.nih.gov/protein/AAF29689 ; 2000.	
	54	MELLORS et al., "Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance," <i>Mutations in RT and Protease</i> , 1995; III-93-III-105.	
	55	PARIKH et al., "Mutations in Retroviral Genes Associated with Drug Resistance," <i>HIV Database Review</i> , 2000; 106-161.	
	56	PATICK et al., "Antiviral and Resistance Studies of AG1343, an Orally Bioavailable Inhibitor of Human Immunodeficiency Virus Protease," <i>Antimicrobial Agents and Chemotherapy</i> ; 1996; 40(2):292-297.	
	57	PAULOUS et al., "A 1 Week, Single-Cycle Protease Inhibitor Resistance Assay," <i>International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, Session 3</i> , 1997; Abstract 46.	
	58	PAUWELS et al., "Rapid and Automated Tetrazolium-based Colorimetric Assay for the Detection of Anti-HIV Compounds," <i>Journal of Virological Methods</i> , 1988; 20(4):309-321.	
	59	PAUWELS et al., "A Comprehensive HIV Drug Resistance Monitoring Using Rapid, High-Throughput Phenotypic and Genotypic Assays with Correlative Data Analysis," <i>2nd Annual Workshop on HIV Drug Resistance and Treatment Strategies</i> , Lake Maggiore, Italy, 1998; Abstract 51.	
	60	PROUDFOOT et al., "Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4.1 2-Substituted Dipyrroliodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes," <i>Journal of Medical Chemistry</i> , 1995; 38(24):4830-4838.	
	61	RICHMAN et al., "Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected during Therapy," <i>Journal of Virology</i> , 1994; 68(3):1660-1666.	
	62	RICHMAN et al., "Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction," <i>Journal of Infectious Diseases</i> , 1991; 164:1075-1081.	
	63	ROBINSON et al., "HIV Type 1 Protease Cleavage Site Mutations and Viral Fitness: Implications for Drug Susceptibility Phenotyping Assays," <i>AIDS Research and Human Retroviruses</i> , 2000; 16(12):1149-1156.	
	64	SCHINAZI et al., "Mutations in Retroviral Genes Associated with Drug Resistance," <i>International Antiviral News</i> , 2000; 8(5):65-91.	
	65	SCHMIDT et al., "pol protein (HIV-1)", downloaded from http://www.ncbi.nlm.nih.gov/protein/AAK32676 ; 2002: 1-2.	
	66	SCHMIDT et al., "HIV-1 isolate 992286 from Germany pol protein (pol) gene", downloaded from http://www.ncbi.nlm.nih.gov/nucleotide/AF347471 ; 2002: 1-2.	
	67	SCHMIT et al., "Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)," <i>AIDS</i> , 1996; 10:995-999	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,436-Conf. #7541
				Filing Date	December 22, 2004
				First Named Inventor	Hilde Azijn
				Art Unit	1648
				Examiner Name	L. W. Z. Humphrey
Sheet	5	of	5	Attorney Docket Number	026038.0248PTUS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	68	SHAHER et al., "Highly Active Antiretroviral Therapy for the Treatment of Infection with Human Immunodeficiency Virus Type 1," <i>Biomedicine & Pharmacotherapy</i> , 1999; 53:73-86.	
	69	SHAHER et al., "Online Comparison of HIV-1 Drug Resistance Algorithms Identifies Rates and Causes of Discordant Interpretations," <i>Antiviral Therapy</i> , 2001; 6(Supplement 1):101-102.	
	70	SHAHER et al., "HIV-1 isolate PCCPROT48 from USA, protease (pol) gene", downloaded from http://www.ncbi.nlm.nih.gov/nucleotide/AF085133 ; 2001.	
	71	VERGNE et al., "POL precursor [HIV1]" downloaded from http://www.ncbi.nlm.nih.gov/protein/CAC03089 , 2000: 1-2.	
	72	WATKINS et al., "Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 2003; 47(2):759-769.	
	73	WATKINS et al., "Protease HIV1", downloaded from http://www.ncbi.nlm.nih.gov/protein/Q7ZCQ9 , 2000.	
	74	ZOLOPA et al., "HIV-1 Genotypic Resistance Patterns Predict Response to Saquinavir-Ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed", <i>Annals of Internal Medicine</i> , 1999; 131(11): 813-821.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--